Columbia University-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

2014

  1. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies

    Leukemia